CHEMGENEX will have to answer some tough questions when it faces the FDA’s Oncologic Drugs Advisory Committee – but not tomorrow, as planned, as wild weather in the US has forced the regulator to delay its planned meeting to consider the fate of chronic myeloid leukaemia drug Omapro.

Click here to read the rest of today's news stories.